Astellas has struck a deal with fellow Japanese pharma company Elpiscience to develop up to four cancer immunotherapies that work by revving up the activity of macrophages against tumour cells.The deal – which includes upfront and near-term payments of up to $37 million, research funding, and more than $1.7 billion in milestone payments – centres […]
